‘Encouraging’ Early Data for mRNA Vaccine in Glioblastoma
BARCELONA — In a first-in-human clinical trial, an investigational messenger RNA (mRNA)-based cancer vaccine for glioblastoma induced tumor-associated antigen-specific T-cell responses in more than three quarters of patients and had an acceptable safety profile. “These early data are encouraging,” Ghazaleh Tabatabai, MD, PhD, University Hospital Tübingen…
Read More
0
